✦ LIBER ✦

Ibandronate treatment for osteoporosis: Rationale, preclinical and clinical development of extended dosing regimens

✍ Scribed by Solomon Epstein

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and Preclinical Rationale for C

✍ Stewart J. Tepper; Mark J. Stillman 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB

Inhibition of RANKL as a treatment for o

✍ Michael R. McClung 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 99 KB

Novel compounds in preclinical/early cli

✍ Erik De Clercq 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 1 views

“Renal-dose” dopamine for the treatment

✍ Denton, Mark D; Chertow, Glenn M; Brady, Hugh R 📂 Article 📅 1996 🏛 Nature Publishing Group 🌐 English ⚖ 919 KB

The effect on bone mass and bone markers

✍ P. Ravn; B. Clemmesen; B. J. Riis; C. Christiansen 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 43 KB

Percentage of anti-CD4 monoclonal antibo

✍ Ernest H. S. Choy; Costantino Pitzalis; Alberto Cauli; J. A. Bijl; Allen Schantz 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB